ICAD - アイキャド （icad inc.） アイキャドICADのチャート
ICADの企業情報
| symbol | ICAD |
|---|---|
| 会社名 | iCAD inc （アイキャド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | コンピュ―タ―ハ―ドウェア 医療関連（Health Care） |
| 概要 | 事業概要 アイ・シーエーディー(iCAD Inc.)は高度な画像解析とワークフローソリューションの提供を行い、医療従事者に対して、患者において高頻度に見られるがんの早期特定と病理の早期識別を可能にする。同社はマンモグラフィー、磁気共鳴イメージング（MRI）やコンピュータ断層撮影（CT）を対象に一連のアップグレード可能なコンピュータ支援検出（CAD）システムやワークフローソリューションを提供する。同社のソリューションは放射線科医に対して、患者において高頻度に見られるがんの特定と病理の識別を可能にする。同社のデジタル及びMRI CAD製品は乳房撮影（マンモグラフィー）、乳房および前立腺のMRI画像診断、及びCTコロノグラフィー用の高度な画像解析とワークフローソリューションを含む。同社のフィルムベースの製品はマンモグラフィ・フィルムをデジタル画像に変換する製品を含む。同社の電子ブラキセラピー製品は乳がん治療用の電子ブラキセラピー（Ebx）療法を含む。 アイキャドは、米国の画像診断システム販売会社。癌の早期発見と治療のために、画像解析、ワ―クフロ―ソリュ―ションと放射線療法を提供する。マンモグラフィ用コンピュ―タ支援検出(CAD)ソリュ―ションを販売。また、結腸ポリ―プを検出する仮想大腸内視鏡検査やCTコロノグラフィ―(CTC)で使用するためのCADソリュ―ションを開発する。 iCAD Inc., headquartered in Nashua, New Hampshire, is a medical-device manufacturer. iCAD makes cancer detection and radiation therapy devices. iCAD offers computer aided detection and workflow solutions to support detection of breast, prostate and colorectal cancers. |
| 本社所在地 | 98 Spit Brook Road Suite 100 Nashua NH 03062 USA |
| 代表者氏名 | Lawrence Howard ローレンスハワード |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 603-882-5200 |
| 設立年月日 | 30713 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 119人 |
| url | www.icadmed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/icad |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -7.46900 |
| 終値（lastsale） | 3.115 |
| 時価総額（marketcap） | 52527425.755 |
| 時価総額 | 時価総額（百万ドル） 52.27448 |
| 売上高 | 売上高（百万ドル） 27.37700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 50.55348 |
| 当期純利益 | 当期純利益（百万ドル） 3.62400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 iCAD Inc revenues decreased 5% to $12.5M. Net loss increased 40% to $4.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Detection segment income decrease of 22% to $1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.19 to -$0.26. |
ICADのテクニカル分析
ICADのニュース
The 3 Best Millionaire-Maker Stocks to Buy for April 2023 2023/04/07 20:28:16 InvestorPlace
It’s certainly not easy to find millionaire-maker stocks if you only have $50,000 or less to invest. In order to turn that amount of money into $1 million using a single stock, you’ll need vision, a contrary nature, tenacity, and a great deal of patience. The vision and the contrarian part are important, because you’ll need to spot the huge potential of a company that the Street is missing or not yet acting on. Addiitonally, you’ll have to be contrarian enough to invest a significant amount of your money in the stock anyway. The tenacious part is necessary, as the ability to hold onto the stock or even buy more of it as it falls becomes even more important. That’s because investors and short sellers don’t see or don’t care about the company’s huge, long-term opportunities. And of course, you’ll have to have enough patience to hold onto the stock long enough to benefit from the fruits of the company’s victories. Having said all that, here are three potential millionaire-maker stocks. EXAS Exact Sciences $66.36 ESAIY Eisai $14.25 ICAD iCAD $1.32 Exact Sciences (EXAS) Source: Shutterstock First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research.
3 AI Stocks to Buy for the Future of Automation 2023/02/17 15:30:59 InvestorPlace
Since at least 2020, I have recognized the tremendous power of artificial intelligence to change our world in general and companies’ financial results in particular. My belief in the power of AI led me to recommend and, in some cases, buy the shares of Inte l (NASDAQ: INTC ), International Business Machines (NYSE: IBM ), Stem (NYSE: STEM ), iCAD (NASDAQ: ICAD ), Micron (NASDAQ: MU ), Schrodinger (NASDAQ: SDGR ), Upstart (NASDAQ: UPST ), Lemonade (NYSE: LMND ), and, yes, even C3.ai (NYSE: AI ) stock. Unfortunately, largely (but not completely) due to the market’s aversion towards growth stocks since early 2021, those picks (except IBM) worked out poorly. But the times are changing, increasing the likelihood that investors who find good AI stocks to buy will profit over the medium term and the long term. For one, the market is, at last, becoming friendlier to high-tech growth stocks . And, of course, the huge amount of publicity surrounding ChatGPT has made Street and retail investors aware of the vast power of AI.
Why iCAD Inc. (NASDAQ: ICAD) Stock Should Not Be Taken For Granted By Investors In 2023 2023/01/16 19:00:00 Marketing Sentinel
In the last trading session, 0.24 million shares of the iCAD Inc. (NASDAQ:ICAD) were traded, and its beta was 1.17. Most recently the company’s share price was $2.19, and it changed around $0.08 or 3.79% from the last close, which brings the market valuation of the company to $53.70M. ICAD currently trades at a discount … Why iCAD Inc. (NASDAQ: ICAD) Stock Should Not Be Taken For Granted By Investors In 2023 Read More »
A Quick Glance At iCAD Inc. (NASDAQ: ICAD) Stock: It Is up 16.39% From Its 52-Week Low; YTD, It Is Down -74.58 Percent 2022/12/31 16:30:00 Marketing Sentinel
During the last session, iCAD Inc. (NASDAQ:ICAD)’s traded shares were 0.42 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $1.83, reflecting an intraday gain of 8.28% or $0.14. The 52-week high for the ICAD share is $7.57, that puts it down -313.66 … A Quick Glance At iCAD Inc. (NASDAQ: ICAD) Stock: It Is up 16.39% From Its 52-Week Low; YTD, It Is Down -74.58 Percent Read More »
ICAD Rises on Cancer Imaging Deal with Google 2022/11/28 15:20:35 TipRanks
Shares of cancer detection and cancer therapy solutions provider iCAD (NASDAQ:ICAD) are in the green today on the back of its development and commercialization deal with Google (NASDAQ:GOOGL)(NASDAQ:GOOG) . Under the agreement, Google Health’s AI technology will be integrated with ICAD’s breast imaging AI solutions. The two companies will also work on enhancing ICAD’s solutions for mammography and expanding access to the technology. Further, ICAD will utilize the licensed technology from Google to enhance its 3D and 2D AI algorithms and will bring the developed products to market. Despite today’s price gains, ICAD shares are still down nearly 76% over the past year.
3 AI Stocks to Buy for the Future of Automation 2023/02/17 15:30:59 InvestorPlace
Since at least 2020, I have recognized the tremendous power of artificial intelligence to change our world in general and companies’ financial results in particular. My belief in the power of AI led me to recommend and, in some cases, buy the shares of Inte l (NASDAQ: INTC ), International Business Machines (NYSE: IBM ), Stem (NYSE: STEM ), iCAD (NASDAQ: ICAD ), Micron (NASDAQ: MU ), Schrodinger (NASDAQ: SDGR ), Upstart (NASDAQ: UPST ), Lemonade (NYSE: LMND ), and, yes, even C3.ai (NYSE: AI ) stock. Unfortunately, largely (but not completely) due to the market’s aversion towards growth stocks since early 2021, those picks (except IBM) worked out poorly. But the times are changing, increasing the likelihood that investors who find good AI stocks to buy will profit over the medium term and the long term. For one, the market is, at last, becoming friendlier to high-tech growth stocks . And, of course, the huge amount of publicity surrounding ChatGPT has made Street and retail investors aware of the vast power of AI.
Why iCAD Inc. (NASDAQ: ICAD) Stock Should Not Be Taken For Granted By Investors In 2023 2023/01/16 19:00:00 Marketing Sentinel
In the last trading session, 0.24 million shares of the iCAD Inc. (NASDAQ:ICAD) were traded, and its beta was 1.17. Most recently the company’s share price was $2.19, and it changed around $0.08 or 3.79% from the last close, which brings the market valuation of the company to $53.70M. ICAD currently trades at a discount … Why iCAD Inc. (NASDAQ: ICAD) Stock Should Not Be Taken For Granted By Investors In 2023 Read More »
A Quick Glance At iCAD Inc. (NASDAQ: ICAD) Stock: It Is up 16.39% From Its 52-Week Low; YTD, It Is Down -74.58 Percent 2022/12/31 16:30:00 Marketing Sentinel
During the last session, iCAD Inc. (NASDAQ:ICAD)’s traded shares were 0.42 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $1.83, reflecting an intraday gain of 8.28% or $0.14. The 52-week high for the ICAD share is $7.57, that puts it down -313.66 … A Quick Glance At iCAD Inc. (NASDAQ: ICAD) Stock: It Is up 16.39% From Its 52-Week Low; YTD, It Is Down -74.58 Percent Read More »
ICAD Rises on Cancer Imaging Deal with Google 2022/11/28 15:20:35 TipRanks
Shares of cancer detection and cancer therapy solutions provider iCAD (NASDAQ:ICAD) are in the green today on the back of its development and commercialization deal with Google (NASDAQ:GOOGL)(NASDAQ:GOOG) . Under the agreement, Google Health’s AI technology will be integrated with ICAD’s breast imaging AI solutions. The two companies will also work on enhancing ICAD’s solutions for mammography and expanding access to the technology. Further, ICAD will utilize the licensed technology from Google to enhance its 3D and 2D AI algorithms and will bring the developed products to market. Despite today’s price gains, ICAD shares are still down nearly 76% over the past year.
Ferrum Health to Offer iCAD''s Breast AI Technologies within its Women''s Health AI Hub 2022/11/23 22:07:00 Kwhen Finance
iCAD Inc. (NASDAQ: ICAD) Prices Could Soar To Much Higher Levels In Coming Months 2022/09/05 14:30:00 Marketing Sentinel
In the last trading session, 61346.0 iCAD Inc. (NASDAQ:ICAD) shares changed hands as the company’s beta touched 1.09. With the company’s per share price at $2.97 changed hands at $0.03 or 1.02% during last session, the market valuation stood at $75.26M. ICAD’s last price was a discount, traded about -328.62% off its 52-week high of … iCAD Inc. (NASDAQ: ICAD) Prices Could Soar To Much Higher Levels In Coming Months Read More »
Global Mammography Market Analysis Report 2022: Transformational Growth Driven by Disruptive AI Solutions Enhancing Workflow Efficiency and Clinical Decision-Making 2022/08/29 20:00:00 Kwhen Finance
iCAD GAAP EPS of -$0.12 misses by $0.01, revenue of $7.57M misses by $1.37M (NASDAQ:ICAD) 2022/08/10 20:20:45 Seeking Alpha
iCAD press release (ICAD): Q2 GAAP EPS of -$0.12 misses by $0.01.Revenue of $7.57M (-3.2% Y/Y) misses by $1.37M.
iCAD Q2 2022 Earnings Preview (NASDAQ:ICAD) 2022/08/09 21:35:25 Seeking Alpha
iCAD (ICAD) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close.The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate…
5 Growth Stocks to Buy Now 2022/05/27 20:44:16 InvestorPlace
This article is excerpted from Tom Yeung’s Profit & Protection newsletter. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . Growth Investing Works On Tuesday, I introduced the Profit & Protection playbook — a good, hard look into beating the markets with data. The big takeaway from that newsletter? Growth investing works. Stocks with high expected growth rates (both sales and earnings) and past growth tend to outperform over the following twelve months. That’s no news to venture capitalists or my Hypergrowth Investing colleague, Luke Lango. But there was a wrinkle: Turnarounds do even better. Stocks that had the worst sales growth in the prior year outperformed their high-growth counterparts by a 1.4-to-1 ratio. I can practically see Warren Buffett and InvestorPlace analyst Eric Fry smiling. But if you’re tired of all this theoretical fluff, I don’t blame you. We’re here for profits, not a lesson in data science or fortune-telling. So today, we’re going to use the Profit & Protection playbook to identify five promising growth stocks that look set to ride out the upcoming 6 to 12 months.